GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001605513 | Endometrium | EEC | Wnt signaling pathway | 90/2168 | 444/18723 | 6.65e-08 | 3.50e-06 | 90 |
GO:019873813 | Endometrium | EEC | cell-cell signaling by wnt | 90/2168 | 446/18723 | 8.25e-08 | 4.23e-06 | 90 |
GO:004341011 | Endometrium | EEC | positive regulation of MAPK cascade | 89/2168 | 480/18723 | 4.21e-06 | 1.08e-04 | 89 |
GO:004312216 | Endometrium | EEC | regulation of I-kappaB kinase/NF-kappaB signaling | 53/2168 | 249/18723 | 7.59e-06 | 1.73e-04 | 53 |
GO:004312314 | Endometrium | EEC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 42/2168 | 186/18723 | 1.47e-05 | 2.87e-04 | 42 |
GO:000724915 | Endometrium | EEC | I-kappaB kinase/NF-kappaB signaling | 57/2168 | 281/18723 | 1.60e-05 | 3.12e-04 | 57 |
GO:003367415 | Endometrium | EEC | positive regulation of kinase activity | 83/2168 | 467/18723 | 4.32e-05 | 7.10e-04 | 83 |
GO:001097513 | Endometrium | EEC | regulation of neuron projection development | 79/2168 | 445/18723 | 6.80e-05 | 1.01e-03 | 79 |
GO:005109013 | Endometrium | EEC | regulation of DNA-binding transcription factor activity | 75/2168 | 440/18723 | 3.71e-04 | 3.97e-03 | 75 |
GO:003134613 | Endometrium | EEC | positive regulation of cell projection organization | 61/2168 | 353/18723 | 8.82e-04 | 8.03e-03 | 61 |
GO:000173812 | Endometrium | EEC | morphogenesis of a polarized epithelium | 21/2168 | 94/18723 | 2.18e-03 | 1.63e-02 | 21 |
GO:00600713 | Endometrium | EEC | Wnt signaling pathway, planar cell polarity pathway | 13/2168 | 52/18723 | 5.34e-03 | 3.31e-02 | 13 |
GO:20000273 | Endometrium | EEC | regulation of animal organ morphogenesis | 24/2168 | 125/18723 | 8.60e-03 | 4.70e-02 | 24 |
GO:00160556 | Lung | IAC | Wnt signaling pathway | 95/2061 | 444/18723 | 1.13e-10 | 2.80e-08 | 95 |
GO:01987386 | Lung | IAC | cell-cell signaling by wnt | 95/2061 | 446/18723 | 1.46e-10 | 3.48e-08 | 95 |
GO:00109756 | Lung | IAC | regulation of neuron projection development | 82/2061 | 445/18723 | 1.82e-06 | 8.78e-05 | 82 |
GO:00336748 | Lung | IAC | positive regulation of kinase activity | 83/2061 | 467/18723 | 6.76e-06 | 2.45e-04 | 83 |
GO:00072495 | Lung | IAC | I-kappaB kinase/NF-kappaB signaling | 56/2061 | 281/18723 | 7.39e-06 | 2.62e-04 | 56 |
GO:00431226 | Lung | IAC | regulation of I-kappaB kinase/NF-kappaB signaling | 51/2061 | 249/18723 | 8.41e-06 | 2.87e-04 | 51 |
GO:00510903 | Lung | IAC | regulation of DNA-binding transcription factor activity | 76/2061 | 440/18723 | 4.44e-05 | 1.05e-03 | 76 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ROR1 | SNV | Missense_Mutation | rs201702143 | c.103N>G | p.Ser35Ala | p.S35A | Q01973 | protein_coding | tolerated_low_confidence(0.82) | benign(0.034) | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ROR1 | SNV | Missense_Mutation | novel | c.1924N>C | p.Ser642Pro | p.S642P | Q01973 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
ROR1 | SNV | Missense_Mutation | rs201702143 | c.103N>G | p.Ser35Ala | p.S35A | Q01973 | protein_coding | tolerated_low_confidence(0.82) | benign(0.034) | TCGA-A2-A0T4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | femara | SD |
ROR1 | SNV | Missense_Mutation | rs201702143 | c.103T>G | p.Ser35Ala | p.S35A | Q01973 | protein_coding | tolerated_low_confidence(0.82) | benign(0.034) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
ROR1 | SNV | Missense_Mutation | rs866734548 | c.1969N>T | p.Arg657Cys | p.R657C | Q01973 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ROR1 | SNV | Missense_Mutation | | c.175N>T | p.Thr59Ser | p.T59S | Q01973 | protein_coding | tolerated(0.65) | benign(0.08) | TCGA-AN-A0FJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ROR1 | SNV | Missense_Mutation | | c.1579N>C | p.Met527Leu | p.M527L | Q01973 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AN-A0XS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ROR1 | SNV | Missense_Mutation | | c.748N>C | p.Asp250His | p.D250H | Q01973 | protein_coding | deleterious(0.04) | probably_damaging(0.997) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ROR1 | SNV | Missense_Mutation | rs749580497 | c.206N>T | p.Thr69Met | p.T69M | Q01973 | protein_coding | tolerated(0.07) | possibly_damaging(0.881) | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ROR1 | SNV | Missense_Mutation | rs139362871 | c.1624N>A | p.Val542Ile | p.V542I | Q01973 | protein_coding | tolerated(0.15) | possibly_damaging(0.544) | TCGA-B6-A0IE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4919 | ROR1 | KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME, CELL SURFACE | | Cirmtuzumab | CIRMTUZUMAB | |
4919 | ROR1 | KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME, CELL SURFACE | | ROR1R-CAR-T Cell | | |
4919 | ROR1 | KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME, CELL SURFACE | | ROR1 CAR-specific Autologous T-Lymphocytes | | |